HIV AIDS drug resistance: Difference between revisions
Jump to navigation
Jump to search
| Line 13: | Line 13: | ||
==Historical Perspective== | ==Historical Perspective== | ||
*Over the past decade, access to ART for HIV has dramatically increased in low- and middle-income countries. From preliminary data, more than 6 million people were receiving ART in these countries at the end of 2010, as compared to just 400 000 at the end of 2003. | *Over the past decade, access to ART for HIV has dramatically increased in low- and middle-income countries. From preliminary data, more than 6 million people were receiving ART in these countries at the end of 2010, as compared to just 400 000 at the end of 2003. | ||
**[[Zidovudine]] (AZT), a [[nucleoside reverse transcriptase inhibitor]] (NRTI), was first administered in 1987, and until 1995, monotherapy or dual therapy with NRTIs were the only treatments available. | **[[Zidovudine]] (AZT), a [[Reverse transcriptase inhibitor#Nucleoside analog reverse transcriptase inhibitors (NARTIs or NRTIs)|nucleoside reverse transcriptase inhibitor]] (NRTI), was first administered in 1987, and until 1995, monotherapy or dual therapy with NRTIs were the only treatments available. | ||
**The first [[protease inhibitor]] (PI), [[saquinavir]], was approved for treatment in 1995, followed closely in 1996 by a [[nonnucleoside reverse transcriptase inhibitor]] (NNRTI), [[nevirapine]]. These new drugs generated a major change in the treatment strategy against HIV—highly active antiretroviral therapy (HAART). | **The first [[protease inhibitor]] (PI), [[saquinavir]], was approved for treatment in 1995, followed closely in 1996 by a [[Reverse transcriptase inhibitor# Non-nucleoside reverse transcriptase inhibitors (NNRTIs) | nonnucleoside reverse transcriptase inhibitor]] (NNRTI), [[nevirapine]]. These new drugs generated a major change in the treatment strategy against HIV—highly active antiretroviral therapy (HAART). | ||
==Current scenario== | ==Current scenario== | ||
Revision as of 14:19, 30 May 2012
Overview
The ability of HIV to mutate and reproduce itself in the presence of antiretroviral drugs is called HIV drug resistance. HIV Drug Resistance occurs when microevolution causes virions to become tolerant to antiretroviral treatments. Drug resistant virus will continue to replicate in the presence of the drug to which it has become resistant.
Etiology
As ART continues to expand, the emergence of some drug resistance is inevitable. Many factors leading to treatment failure and eventually drug resistance are as following:
- Insufficient knowledge among patients and health workers.
- Suboptimal adherence to treatment regimens.
- Drug stock-outs.
- Inadequate patient monitoring mechanisms.
Historical Perspective
- Over the past decade, access to ART for HIV has dramatically increased in low- and middle-income countries. From preliminary data, more than 6 million people were receiving ART in these countries at the end of 2010, as compared to just 400 000 at the end of 2003.
- Zidovudine (AZT), a nucleoside reverse transcriptase inhibitor (NRTI), was first administered in 1987, and until 1995, monotherapy or dual therapy with NRTIs were the only treatments available.
- The first protease inhibitor (PI), saquinavir, was approved for treatment in 1995, followed closely in 1996 by a nonnucleoside reverse transcriptase inhibitor (NNRTI), nevirapine. These new drugs generated a major change in the treatment strategy against HIV—highly active antiretroviral therapy (HAART).
Current scenario
- Nearly all drugs currently used to treat HIV eventually stop working when patient develops resistance to ART. HIV develops resistance when it evades the effects of these treatments.[1] A recent study estimated the percentage of the American HIV positive population with some form of drug resistance to be 76.3%.[2]
- The extent of HIV drug resistance resulting from recent ART scale up in resource-limited countries has not systematically been quantified due to the lack of reliable data and information.
Mechanism of drug resistance
- As a retrovirus, HIV uses the enzyme reverse transcriptase to synthesize DNA from its RNA genome and lacks a mechanism for correcting errors made while reproducing its genome.[1] As a result, HIV replicates its genome with the highest known mutation rate of any living organism.[1] This creates an ideal situation for natural selection to act on the HIV population, as genetic variation is the raw material for natural selection.
- These mutations accumulate over generations and in populations, resulting in the great genetic variation within populations of HIV, and an increased probability of a virion developing an evolutionary selective advantage over other virions.[1] Natural selection then acts on HIV by selecting for virions with higher fitness, as all others are eventually killed off by drug treatments.[3] The virions that are able to escape the harmful effects of the drug then create an entirely new, drug resistant population.
- The virions reproduce until the patient has a population of viruses as large as they originally did before treatment reduced these numbers. This creates a cycle in which patients first experiences success with treatment, as their viral levels decrease, then experiences a decline in treatment effectiveness as the virus develops resistance and rebuilds its population of virus particles.
Consequences of drug resistance
The consequences of drug resistance include
- Treatment failure.
- Increased direct and indirect health costs associated with the need to start more costly second-line treatment for patients.
- The spread of resistant strains of HIV.
- The need to develop new anti-HIV drugs
Strategies against HIV Drug resistance
WHO and its HIV ResNet group of experts and organizations have developed a Global strategy for prevention and assessment of HIV drug resistance. The strategy aims to build evidence on the scale of HIV drug resistance and equip and prepare countries with knowledge, skills and systems to respond should drug-resistant HIV epidemics emerge.
Reference
- ↑ 1.0 1.1 1.2 1.3 Freeman, S., and J. C. Herron. 2007. Evolutionary Analysis. 4th ed. A case for evolutionary thinking: understanding HIV. Pearson Benjamin Cummings, San Francisco, CA.
- ↑ Richman, D. D., S. C. Morton, T. Wrin, N. Hellmann, S. Berry, M. F. Shapiro, and S. A. Bozzette. 2004. The prevalence of antiretroviral drug resistance in the United States. AIDS. 18: 1393-1401.
- ↑ Kozal, M. J. 2009. Drug-resistant human immunodeficiency virus. Clin Microbial Infec. 15 (Suppl. 1): 69-73.